Based on the above findings, not only PFS but also the chance of de novo resistance to first-line EGFR-TKIs, were correlated with PD-L1 expressions in EGFR-mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.